CDX-011: Phase IIb start

This quarter, Celldex will begin a Phase IIb trial in 120 patients to compare 1.88 mg/kg intravenous CDX-011 given on day 1 of each 21-day cycle vs. single agent chemotherapeutic of investigator's cho...